Skip to main content

CD4 T cells produce GM-CSF and drive immune-mediated glomerular disease by licensing monocyte-derived cells to produce MMP12.

Science translational medicine

Authors: Hans-Joachim Paust, Ning Song, Donatella De Feo, Nariaki Asada, Selma Tuzlak, Yu Zhao, Jan-Hendrik Riedel, Malte Hellmig, Amirrtavarshni Sivayoganathan, Anett Peters, Anna Kaffke, Alina Borchers, Ulrich O Wenzel, Oliver M Steinmetz, Gisa Tiegs, Elisabeth Meister, Matthias Mack, Christian Kurts, Sibylle von Vietinghoff, Maja T Lindenmeyer, Elion Hoxha, Rolf A K Stahl, Tobias B Huber, Stefan Bonn, Catherine Meyer-Schwesinger, Thorsten Wiech, Jan-Eric Turner, Burkhard Becher, Christian F Krebs, Ulf Panzer

GM-CSF in glomerulonephritisDespite glomerulonephritis being an immune-mediated disease, the contributions of individual immune cell types are not clear. To address this gap in knowledge, Paust . characterized pathological immune cells in samples from patients with glomerulonephritis and in samples from mice with the disease. The authors found that CD4+ T cells producing granulocyte-macrophage colony-stimulating factor (GM-CSF) licensed monocytes to promote disease by producing matrix metalloproteinase 12 and disrupting the glomerular basement membrane. Targeting GM-CSF to inhibit this axis reduced disease severity in mice, implicating this cytokine as a potential therapeutic target for patients with glomerulonephritis. -CM.

PMID: 36921033

Participating cluster members